XBIT

XBiotech Inc.

NasdaqHealthcarePHARMACEUTICAL PREPARATIONS

Insider activity for last month from Oct 16 to Nov 16.

How these metrics are calculated

Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.

Total buying$855k2 buys
Total selling$00 sales
Net open-market+$855kBuying minus selling
Active insiders1Distinct reporting owners

XBIT transaction history

Newest filings · 20 transactions per page

Latest insider transactions

Form 4 filings from last month.
Newest company filings
InsiderActivityDisclosed valueFiled (ET)
Simard John
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
10% owner buy
The buyer is a beneficial owner of more than 10% of the company.
Director buy
The buyer is identified as a director.
+2
Repeat buyer

The same owner reported more than one buy within 30 days.

Late filing

Filed more than 5 days after the trade. Form 4 is normally due within 2 business days.

SEC filing ↗
$143kView disclosure →
Simard John
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
10% owner buy
The buyer is a beneficial owner of more than 10% of the company.
Director buy
The buyer is identified as a director.
SEC filing ↗
$711kView disclosure →

Insider activity report

Calendar-month buckets within the selected date range

Latest filing: Nov 13, 2026

Open-market transaction mix · 2 transactions in the selected period
2 buys100%·0%0 sells

Code A includes awards, grants and other acquisitions; these are not open-market buys. A rolling period can include partial calendar months.

View exact monthly counts and disclosed values
Monthly activity within the selected period; unknown values remain unknown.
MonthBuysSellsAwards (A)Buy valueSell valueNet P/S value
Oct 2026100$711,251.32$0+$711,251.32
Nov 2026100$143,409$0+$143,409

Distinct insiders active

Reporting-owner CIKs by month · peak Oct 2026 (1)
Oct 2026: 1 insidersNov 2026: 1 insiders
Oct 2026Nov 2026
1distinct insiders in selected period
Largest insider activity
By absolute net disclosed value · current transaction page
1 insider
  • SJ
    Simard JohnDIR · 2 buys · 0 sales · 0 awards (A)
    +$855klast Nov 13
Filing, role and holdings details

Filing-only signals

Deterministic matches in the selected period

Recent filing activity
Most recent 2 transactions on this page · color = transaction code

Filing detail checks

Secondary metrics for the selected period
Largest buy$711k
Largest sale—
10b5-1 detected0
Amended rows0

Transaction codes

By Form 4 transaction code in selected period
2transactionstxns
  • P · Open-market buys · dominant2 · 100%

Activity by reported role

A joint filing can contribute to multiple roles
Director2

Reported Holdings After

Separated by insider, security, and ownership type

Simard JohnCommon Stock · Direct
4.26M4.19MOct 26, 2026Nov 3, 2026
4,261,690Nov 3, 2026

These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.

Filing activity heatmap
Current transaction page only · each cell is a filing date · buys green, sells red
2 active days
Oct 16 → Nov 16
LessMore

XBiotech Inc. Insider Activity FAQ

SEC Form 4 context

Who recently reported transactions at XBiotech Inc.?

SIMARD JOHN.

When was the latest reported open-market purchase?

Simard John reported a buy on Nov 3, 2026 valued at $143k. Read the SEC filing.

When was the latest reported open-market sale?

No code-S sale is available for this period.

What is the recent purchase and sale balance?

Net open-market buying in the selected period was $854,660.32.

Where can I see the original SEC filing?

Every transaction row and latest-activity fact links to its original SEC filing.

What do these Form 4 transaction codes mean?

P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.